Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

Clinical trial NCT05409066 · ACTIVE_NOT_RECRUITING

Trial details

NCT number

NCT05409066

Sponsor

Genmab

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 3

Study type

INTERVENTIONAL

Start date

2022-09-20

Primary completion

2029-12-01

Enrollment

549

View on ClinicalTrials.gov